Formerly called Lexin Pharmaceutical Corporation - Sparta Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company acquires rights to, and develops for commercialization, technologies and pharmaceutical products for the treatment of several life threatening diseases like cancer, cardiovascular disorders and chronic metabolic disorders. During 1998 Sparta successfully completed the Phase I clinical trial for Spartaject busulfan. In January 1999 the company and SuperGen Inc entered into an agreement and plan of reorganization pursuant to which a subsidiary of SuperGen Inc merged with & into the company. Sparta operates as a wholly owned subsidiary of SuperGen Inc
